<p>
<strong>OctoPlus</strong> is a drug delivery company specialized in the development of improved pharmaceutical products that are based on <strong>OctoPlus</strong>' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. In addition, the group is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.</p>
<ul>
<li>
Net sales break down by source of income as follows: sales of services (97.9%), licensing revenues (1.9%) and subsidies (0.2%).</li>
<li>
Net sales are distributed geographically as follows: Europe (28.6%), North America (60.6%) and other (10.8%).</li>
</ul>